Systems and methods for driving negative pressure sources in negative pressure therapy systems

Information

  • Patent Grant
  • 11305047
  • Patent Number
    11,305,047
  • Date Filed
    Wednesday, May 3, 2017
    7 years ago
  • Date Issued
    Tuesday, April 19, 2022
    2 years ago
Abstract
Embodiments of negative pressure wound therapy systems and methods are disclosed. In one embodiment, an apparatus includes a source of negative pressure, a coupling circuit, a driving circuit, and a controller. The driving circuit supplies a driving signal to the source of negative pressure via the coupling circuit to cause the source of negative pressure to provide negative pressure to a wound dressing. The coupling circuit includes an inductive reactance that limits a rate of change over time of the driving signal. The controller controls the driving signal supplied by the driving circuit.
Description
BACKGROUND

Embodiments of the present disclosure relate to methods and apparatuses for dressing and treating a wound with negative or reduced pressure therapy or topical negative pressure (TNP) therapy. In particular, but without limitation, embodiments disclosed herein relate to negative pressure therapy devices, methods for controlling the operation of TNP systems, and methods of using TNP systems.


SUMMARY

In some embodiments, an apparatus for applying negative pressure to a wound is disclosed. The apparatus can include a source of negative pressure, a coupling circuit, a driving circuit, and a controller. The source of negative pressure can provide negative pressure via a fluid flow path to a wound dressing placed over the wound. The source of negative pressure can include an actuator configured to convert an electrical energy to a mechanical energy. The coupling circuit can include an inductive reactance. The driving circuit can supply a driving signal to the actuator via the coupling circuit to cause the source of negative pressure to provide negative pressure. The controller can control the driving signal supplied by the driving circuit.


The apparatus of the preceding paragraph can include one or more of the following features: The actuator can generate negative pressure by converting the electrical energy to the mechanical energy without converting the electrical energy to a magnetic energy. The source of negative pressure can include a piezoelectric pump, and the actuator can include a piezoelectric transducer. The source of negative pressure can include a micropump. The apparatus can further include the wound dressing, and the source of negative pressure can be disposed on or within the wound dressing. The coupling circuit can limit a rate of change over time of the driving signal supplied from the driving circuit to the actuator. The inductive reactance can be greater than 5 mΩ at an operating frequency of 1 kHz. The coupling circuit can include an inductor electrically coupled in series between an output of the driving circuit and an input of the actuator. The inductor can have an inductance between 1 μH and 100 μH. The inductor can have a maximum current rating of at least 1 A. The coupling circuit can include an electrical short electrically coupled in series between another output of the driving circuit and another input of actuator. The driving circuit can include an H-bridge circuit. The controller can further provide a control signal to the driving circuit, and the controller can control the driving signal by adjusting a pulse width modulation of the control signal. A magnitude of the driving signal can be less than 50 V.


A method of operating, using, or manufacturing the apparatus of the preceding two paragraphs is also disclosed.


In some embodiments, a method of operating a negative pressure wound therapy apparatus is disclosed. The method can include: generating and outputting a control signal; activating a plurality of switches responsive to the control signal; supplying a driving signal to an actuator of a source of negative pressure via the plurality of switches; limiting a rate of change over time of the driving signal; and supplying negative pressure with the source of negative pressure to a wound dressing responsive to the driving signal.


The method of the preceding paragraph can include one or more of the following features: The limiting the rate of change over time can include limiting the rate of change over time using an inductive reactance. The supplying negative pressure can be performed by converting an electrical energy to a mechanical energy without converting the electrical energy to a magnetic energy. The activating the plurality of switches can include activating pairs of the plurality of switches responsive to the control signal. The control signal can include a square waveform having a duty cycle of 50%.





BRIEF DESCRIPTION OF THE DRAWINGS

Features and advantages of the present disclosure will be apparent from the following detailed description, taken in conjunction with the accompanying drawings of which:



FIG. 1 illustrates a negative pressure therapy system according to some embodiments.



FIGS. 2A and 2B respectively illustrate a side view and top view of a negative pressure therapy system according to some embodiments, such as the negative pressure therapy system of FIG. 1.



FIG. 3 illustrates a block diagram of electrical communication paths between a power source, control circuitry, and negative pressure source, as well as components of the control circuitry, according to some embodiments.



FIGS. 4A and 4B illustrate simplified circuit components of a driving circuit according to some embodiments.



FIG. 4C illustrates circuit components of a driving circuit according to some embodiments.



FIG. 5 illustrates circuit components of a coupling circuit according to some embodiments.



FIG. 6 illustrates a therapy control process performable by a negative pressure therapy system according to some embodiments.





DETAILED DESCRIPTION

The present disclosure relates to methods and apparatuses for dressing and treating a wound with reduced pressure therapy or topical negative pressure (TNP) therapy. In particular, but without limitation, embodiments of this disclosure relate to negative pressure therapy apparatuses, methods for controlling the operation of TNP systems, and methods of using TNP systems. The methods and apparatuses can incorporate or implement any combination of the features described below.


Many different types of wound dressings are known for aiding in the healing process of a human or animal. These different types of wound dressings include many different types of materials and layers, for example, gauze, pads, foam pads or multi-layer wound dressings. TNP therapy, sometimes referred to as vacuum assisted closure, negative pressure wound therapy, or reduced pressure wound therapy, can be a beneficial mechanism for improving the healing rate of a wound. Such therapy is applicable to a broad range of wounds such as incisional wounds, open wounds and abdominal wounds or the like.


TNP therapy can assist in the closure and healing of wounds by reducing tissue oedema, encouraging blood flow, stimulating the formation of granulation tissue, removing excess exudates, and reducing bacterial load and thus, infection to the wound. Furthermore, TNP therapy can permit less outside disturbance of the wound and promote more rapid healing.


As is used herein, reduced or negative pressure levels, such as −X mmHg, represent pressure levels that are below atmospheric pressure, which typically corresponds to 760 mmHg (or 1 atm, 29.93 inHg, 101.325 kPa, 14.696 psi, etc.). Accordingly, a negative pressure value of −X mmHg reflects pressure that is X mmHg below atmospheric pressure, such as a pressure of (760−X) mmHg. In addition, negative pressure that is “less” or “smaller” than −X mmHg corresponds to pressure that is closer to atmospheric pressure (e.g., −40 mmHg is less than −60 mmHg). Negative pressure that is “more” or “greater” than −X mmHg corresponds to pressure that is further from atmospheric pressure (e.g., −80 mmHg is more than −60 mmHg).


Overview


A driving circuit of a TNP apparatus can supply a driving signal (for example, an electrical current and voltage) to a negative pressure source of the TNP apparatus via a coupling circuit of the TNP apparatus. The negative pressure source can include a pump like a piezoelectric pump or micropump. The coupling circuit can have an inductive reactance that limits a rate of change over time of the driving signal supplied by the driving circuit to the negative pressure source. Advantageously, in certain embodiments, the TNP apparatus having such a construction may consume less power to generate negative pressure than other TNP apparatuses.


Reduced Pressure Therapy Systems and Methods



FIG. 1 illustrates a negative pressure therapy system 100 that includes a TNP apparatus 11 and a wound 14 according to some embodiments. The TNP apparatus 11 can be used to treat the wound 14. The TNP apparatus 11 can include control circuitry 12A, memory 12B, a negative pressure source 12C, a user interface 12D, a power source 12E, a first pressure sensor 12F, and a second pressure sensor 12G that are configured to electrically communicate with one another. In addition, the TNP apparatus 11 can include a wound dressing 13. The power source 12E can provide power to one or more components of the TNP apparatus 11.


One or more of the control circuitry 12A, memory device 12B, negative pressure source 12C, user interface 12D, power source 12E, first pressure sensor 12F, and second pressure sensor 12G can be integral with, incorporated as part of, attached to, or disposed in the wound dressing 13. The TNP apparatus 11 can accordingly be considered to have its control electronics and pump on-board the wound dressing 13 rather than separate from the wound dressing 13.


The control circuitry 12A can include one or more controllers (for example, a microcontroller or microprocessor), activation circuits, boost converters, current limiters, feedback conditioning circuits, and H-bridge inverters. The control circuitry 12A can control the operations of one or more other components of the TNP apparatus 11 according at least to instructions stored in the memory device 12B. The control circuitry 12A can, for instance, control operations of and supply of negative pressure by the negative pressure source 12C.


The negative pressure source 12C can include a pump, such as, without limitation, a rotary diaphragm pump or other diaphragm pump, a piezoelectric pump, a peristaltic pump, a piston pump, a rotary vane pump, a liquid ring pump, a scroll pump, a pump operated by a piezoelectric transducer, or any other suitable pump or micropump or any combinations of the foregoing. The pump can include an actuator driven by a source of energy, such as electrical energy, mechanical energy, and the like. For example, the actuator can be an electric motor, a piezoelectric transducer, a voice coil actuator, an electroactive polymer, a shape-memory alloy, a comb drive, a hydraulic motor, a pneumatic actuator, a screw jack, a servomechanism, a solenoid actuator, a stepper motor, a plunger, a combustion engine, and the like. In some embodiments, the negative pressure source 12C can supply negative pressure by converting electrical energy to mechanical energy without converting the electrical energy to magnetic energy. In such embodiments, the negative pressure source 12C can have a different impact when electrically coupled to one or more other components of the control circuitry 12A than if the negative pressure source 12C supplied negative pressure by converting the electrical energy to the magnetic energy and then to the mechanical energy.


The user interface 12D can include one or more elements that receive user inputs or provide user outputs to a patient or caregiver. The one or more elements that receive user inputs can include buttons, switches, dials, touch screens, or the like, and the one or more elements that provide user outputs can include activation of a light emitting diode (LED) or one or more pixels of the display or activation of a speaker or the like. In one example, the user interface 12D can include a switch to receive user inputs (for instance, a negative pressure activation or deactivation input) and two LEDs to indicate an operating status (for example, functioning normally, under fault condition, or awaiting user input) of the TNP apparatus 11.


The first pressure sensor 12F can be used to monitor pressure underneath the wound dressing 13, such as pressure in a fluid flow path connecting the negative pressure source 12C and the wound 14, pressure at the wound 14, or pressure in the negative pressure source 12C. The second pressure sensor 12G can be used to monitor pressure external to the wound dressing 13. The pressure external to the wound dressing can be atmospheric pressure; however, the atmospheric pressure can vary depending on, for instance, an altitude of use or pressurized environment in which the TNP apparatus 11 may be used.


The control circuitry 12A can control the supply of negative pressure by the negative pressure source 12C according at least to a comparison between the pressure monitored by the first pressure sensor 12F and the pressure monitored by the second pressure sensor 12G.


The wound dressing 13 can include a wound contact layer, a spacer layer, and an absorbent layer. The wound contact layer can be in contact with the wound 14. The wound contact layer can include an adhesive on the patient facing side for securing the dressing to the skin surrounding the wound 14 or on the top side for securing the wound contact layer to a cover layer or other layer of the wound dressing 13. In operation, the wound contact layer can provide unidirectional flow so as to facilitate removal of exudate from the wound while blocking or substantially preventing exudate from returning to the wound 14. The spacer layer can assist in distributing negative pressure over the wound site and facilitating transport of wound exudate and fluids into the wound dressing 13. Further, the absorbent layer can absorb and retain exudate aspirated from the wound 14.


The control circuitry 12A can monitor the activity of the negative pressure source 12C, which may include monitoring a duty cycle of the negative pressure source 12C (for example, the duty cycle of the actuator of the negative pressure source). As is used herein, the “duty cycle” can reflect the amount of time the negative pressure source 12C is active or running over a period of time. In other words, the duty cycle can reflect time that the negative pressure source 12C is in an active state as a fraction of total time under consideration. Duty cycle measurements can reflect a level of activity of the negative pressure source 12C. For example, the duty cycle can indicate that the negative pressure source 12C is operating normally, working hard, working extremely hard, etc. Moreover, the duty cycle measurements, such as periodic duty cycle measurements, can reflect various operating conditions, such as presence or severity of leaks, rate of flow of fluid (for instance, air, liquid, or solid exudate, etc.) aspirated from a wound, or the like. Based on the duty cycle measurements, such as by comparing the measured duty cycle with a set of thresholds (for instance, determined in calibration), the controller can execute or be programmed to execute algorithms or logic that control the operation of the system. For example, duty cycle measurements can indicate presence of a high leak, and the control circuitry 12A can be programmed to indicate this condition to a user (for instance, patient, caregiver, or physician) or temporarily suspend or pause operation of the source of negative pressure in order to conserve power.


When the TNP apparatus 11 may be used to treat the wound 14, the wound dressing 13 can create a substantially sealed or closed space around the wound 13 and under the wound dressing 13, and the first pressure sensor 12F can periodically or continuously measure or monitor a level of pressure in this space. The control circuitry 12A can control the level of pressure in the space between a first negative pressure set point limit and at least a second negative pressure set point limit. In some instances, the first set point limit can be approximately −70 mmHg, or from approximately −60 mmHg or less to approximately −80 mmHg or more. In some instances, the second set point limit can be approximately −90 mmHg, or from approximately −80 mmHg or less to approximately −100 mmHg or more.



FIG. 2A illustrates a side view of a negative pressure therapy system 200, and FIG. 2B illustrates a top view of the negative pressure therapy system 200 according to some embodiments. The negative pressure therapy system 200 can be an example implementation of the negative pressure therapy system 100.


In the negative pressure therapy system 200, the wound dressing 13 of the TNP apparatus 11 is shown as attached to the wound 14. Arrows depict the flow of air through the wound dressing 13 and wound exudate from the wound 14. The TNP apparatus 11 can include an air exhaust 26 and a component area 25, such as a components housing or storage area for components of the TNP apparatus 11 like one or more of the control circuitry 12A, memory device 12B, negative pressure source 12C, user interface 12D, power source 12E, first pressure sensor 12F, and second pressure sensor 12G.


The user interface 12D of the negative pressure therapy system 200 can include a switch 21 (such as a dome switch), a first indicator 23 (such as a first LED), and a second indicator 24 (such as a second LED). The switch 21 can receive a negative pressure activation or deactivation user input (for example, such as receiving the activation or deactivation user input in response to depression of the switch 21 for a period of time, like from between 0.5 seconds and 5 seconds). The first indicator 23 and the second indicator 24 can indicate an operating status like functioning normally, under fault condition, or awaiting user input. In some implementations, the switch 21 can couple to a power supply connection of the negative pressure source 12C or the control circuitry 12A or an enable signal of the negative pressure source 12C or the control circuitry 12A to activate or deactivate supply of negative pressure or disable supply of negative pressure.


Component parts of the wound dressing 13 of the negative pressure therapy system 200 are illustrated to include an airlock layer 27, an absorbing layer 28, and a contact layer 29. The airlock layer 27 can enable air flow. The absorbing layer 28 can absorb wound exudate. The contact layer 29 can be soft and include silicon and be used to couple the TNP apparatus 11 to the patient.



FIG. 3 illustrates a block diagram 300 depicting example electrical communication paths between the power source 12D, control circuitry 12A, and negative pressure source 12C, as well as example components of the control circuitry 12A including a controller 31, a current limiter 32, a driving circuit 33, a feedback conditioner 34, and the coupling circuit 35. FIG. 3 shows, in particular, how the controller 31 can be used to control the supply of negative pressure by the negative pressure source 12C according to some embodiments.


The power source 12D can include one or more power supplies, such as batteries (such as, multiple 3 V batteries) or a connection to mains power, to provide power for one or more components of the TNP apparatus 11. The power source 12D can, for instance, provide electrical current and voltage to the current limiter 32. The voltage output by the power source 12D can be around 30 V, such as 29 V±1 V, in some implementations. The power source 12D can additionally include circuitry, such as a boost converter, to control the electrical current and voltage provided to the current limiter 32.


The current limiter 32 can serve to limit or clamp the current at a maximum current level, such as at 100 mA, 250 mA, 466 mA, 500 mA, or 1 A, to limit potential fault current through the driving circuit 33 and the negative pressure source 12C. Under normal operation (for example, in most or some instances), the current limiter 32 may not operate to limit current or voltage.


The current limiter 32 can provide electric current and voltage to the driving circuit 33. The driving circuit 33 can include an H-bridge circuit composed of multiple switches. The H-bridge can be constructed to operate as an H-bridge inverter. The driving circuit 33 can provide feedback to the controller 31 via the feedback conditioner 34. The feedback conditioner 34 can be used, for instance, to condition current feedback information from the driving circuit 33 before the current feedback information is provided to the controller 31. In one example, the feedback conditioner 34 can include a low-pass filter (which can, for example, include active circuit components) to filter switching noise caused by the switching of one or more switches of the driving circuit 33. The controller 31 can, in turn, control the operations of the driving circuit 33 based on the feedback, in some instances.


The controller 31 can control operations of the driving circuit 33, and in turn the negative pressure source 12C, by outputting one or more control signals via one or more outputs of the controller 31 to one or more inputs of the driving circuit 33. For example, the controller 31 can output a first control signal via a first output O1 of the controller 31 to a first input I1 of the driving circuit 33 and a second control signal via a second output O2 of the controller 31 to a second input I2 of the driving circuit 33. The controller 31 can vary a pulse width modulation (PWM) of the first and second control signals to adjust an electrical current and voltage provided by the driving circuit 33 to the coupling circuit 35 and then to the negative pressure source 12C. The electrical current or voltage provided by the driving circuit 33 may, in some instances, be referred to herein as a driving signal.


In one implementation, the driving circuit 33 can include an H-bridge, and the controller 31 can generate the first and second control signals to cause the H-bridge to output the driving signal having a square waveform (such as ±3 V, ±5 V, ±10 V, ±15 V, ±20 V, ±25 V, ±30 V, or ±40 V) with a frequency (such as 10 kHz to 32 kHz, 14 kHz to 28 kHz, 18 kHz to 24 kHz, 20 KHz to 22 KHz, or about 21 kHz) and a duty cycle or ratio (such as 20%, 30%, 40%, 45%, 50%, 55%, 60%, 70%, or 80%) via a first output O1 of the driving circuit 33 and a second output O2 of the driving circuit 33.


The driving circuit 33 can control supply negative pressure by the negative pressure source 12C by providing the driving signal to the negative pressure source 12C (for example, to the actuator of the negative pressure source 12C) via the coupling circuit 35. The driving circuit 33 can, for instance, output electrical currents via the first and second outputs O1 and O2 of the driving circuit 33 to a first input I1 of the coupling circuit 35 and a second input I2 of the coupling circuit 35. The coupling circuit 35 can, in turn, output electrical currents via a first output O1 of the coupling circuit 35 and a second output O2 of the coupling circuit 35 to a first input I1 of the negative pressure source 12C and a second input I2 of the negative pressure source 12C. The electrical currents output by the driving circuit 33 and the coupling circuit 35 can notably be considered to result in positive charge flowing away from the driving circuit 33 (that is, sourcing of electrical current by the driving circuit 33) or toward the driving circuit 33 (that is, sinking of electrical current by the driving circuit 33).


The coupling circuit 35 can serve to limit a rate of change over time of the current supplied by the driving circuit 33 to the negative pressure source 12C or limit a rate of change over time of a voltage across first and second inputs I1 and I2 of the negative pressure source 12C. The coupling circuit 35 can have an inductive reactance greater than 1 mΩ, 5 mΩ, 10 mΩ, 50 mΩ, 100 mΩ, 500 mΩ, 750 mΩ at an operating frequency of 1 kHz. In some embodiments, the coupling circuit 35 can include passive circuit elements and not include active circuit elements, but in other embodiments, the coupling circuit 35 can include one or both of passive circuit elements and active circuit elements.



FIGS. 4A and 4B illustrate example simplified circuit components of the driving circuit 33 according to some embodiments. As can be seen from FIGS. 4A and 4B, the driving circuit 33 can be composed of at least four switches, including a first switch S1, a second switch S2, a third switch S3, and a fourth switch S4 but together form an H-bridge. The first and fourth switches S1 and S4 can be closed at the same time and the second and third switches S2 and S3 can be opened at the same time, as shown in FIG. 4A, to supply a first current i1 in a first direction through the coupling circuit 35 and the negative pressure source 12C. The second and third switches S2 and S3 can be closed at the same time and the first and fourth switches S1 and S4 can be opened at the same time, as shown in FIG. 4B, to supply a second current i2 in a second direction through the coupling circuit 35 and the negative pressure source 12C. The first direction can be opposite the second direction.



FIG. 4C illustrates example circuit components of the driving circuit 33 (an H-bridge in the illustrated example) that include a resistor 42 according to some embodiments. In the example circuit components shown in FIG. 4C, the electrical current that travels through the resistor 42 can be the same or substantially the same as the electrical current that travels through the coupling circuit 35 and the negative pressure source 12C (for example, the actuator of the negative pressure source 12C). As a result, a feedback provided to the feedback conditioner 34 can, for instance, be a voltage level or drop across the resistor 42, which can be proportional to the electrical current that travels through the resistor 42, as well as the electrical current that travels through the coupling circuit 35 and the negative pressure source 12C. The resistor 42 thus can be used to measure one or more properties of the electrical current, such as a magnitude, that is fed to the negative pressure source 12C via the coupling circuit 35, such as via an inductor of the coupling circuit 35 like an inductor 52 described with respect to FIG. 5. The resistor 42 can be coupled to a low-pass filter, as described herein.



FIG. 5 illustrates example circuit components of the coupling circuit 35 according to some embodiments. As can be seen from FIG. 5, the coupling circuit 35 can include (i) the inductor 52 electrically coupled in series between the first output O1 of the driving circuit 33 and the first input I1 of the negative pressure source 12C and (ii) a wire or an electrical short 54 electrically coupled in series between the second output O2 of the driving circuit 23 and the second input I2 of the negative pressure source 12C. The inductor can have an inductance ranging from 0.1 μH to 1000 μH, 1 μH to 100 μH, or 3 μH to 10 μH, or an inductance of about 7.5 μH. The inductor can have a maximum current rating of greater than 0.25 A, 0.5 A, 0.75 A, 1 A, or 1.25 A. The inductor 52 can be used to oppose rapid changes in a current or voltage supplied to drive the negative pressure source 12C.


In another embodiment, the coupling circuit 35 can include (i) a first wire or a first electrical short electrically coupled in series between the first output O1 of the driving circuit 33 and the first input I1 of the negative pressure source 12C and (ii) a second wire or a second electrical short electrically coupled in series between the second output O2 of the driving circuit 33 and the second input I2 of the negative pressure source 12C.


In yet another embodiment, the coupling circuit 35 can include (i) a first wire or a first electrical short electrically coupled in series between the first output O1 of the driving circuit 33 and the first input I1 of the negative pressure source 12C and (ii) an inductor (such as the inductor 52) electrically coupled in series between the second output O2 of the driving circuit 33 and the second input I2 of the negative pressure source 12C.


In yet a further embodiment, the coupling circuit 35 can include (i) a first inductor (such as the inductor 52) electrically coupled in series between the first output O1 of the driving circuit 33 and the first input I1 of the negative pressure source 12C and (ii) a second inductor (such as the inductor 52) electrically coupled in series between the second output O2 of the driving circuit 33 and the second input I2 of the negative pressure source 12C.


In certain implementations, one or more active elements can be used in place of or in addition to one or more inductors.



FIG. 6 illustrates a therapy control process 600 performable by an apparatus, such as the TNP apparatus 11 according to some embodiments. For convenience, the therapy control process 600 is described in the context of the TNP apparatus 11, but may instead be implemented in other systems described herein, or by other systems not shown.


At block 61, the therapy control process 600 can generate and output a control signal. For example, the controller 31 can generate and output a control signal to the driving circuit 33. At block 62, the therapy control process 600 can activate switches responsive to the control signal. For example, the driving circuit 33 can selectively open and close one or more switches of the driving circuit 33 responsive to the control signal. At block 63, the therapy control process 600 can supply a driving signal via the switches. For example, the driving circuit 33 can supply the driving signal to the coupling circuit 35 via opening and closing of the one or more switches of the driving circuit 33. At block 64, the therapy control process 600 can limit a rate of change over time of the driving signal. For example, the coupling circuit 35 can limit a rate of change over time of the driving signal from the driving circuit 33 using an inductive reactance. At block 65, the therapy control process 600 can supply negative pressure responsive to the driving signal. For example, the negative pressure source 33 can supply negative pressure to the wound dressing 13 responsive to the driving signal provided by the driving circuit 33 via the coupling circuit 35.


Other Variations


Any value of a threshold, limit, duration, etc. provided herein is not intended to be absolute and, thereby, can be approximate. In addition, any threshold, limit, duration, etc. provided herein can be fixed or varied either automatically or by a user. Furthermore, as is used herein relative terminology such as exceeds, greater than, less than, etc. in relation to a reference value is intended to also encompass being equal to the reference value. For example, exceeding a reference value that is positive can encompass being equal to or greater than the reference value. In addition, as is used herein relative terminology such as exceeds, greater than, less than, etc. in relation to a reference value is intended to also encompass an inverse of the disclosed relationship, such as below, less than, greater than, etc. in relations to the reference value. Moreover, although blocks of the various processes may be described in terms of determining whether a value meets or does not meet a particular threshold, the blocks can be similarly understood, for example, in terms of a value (i) being below or above a threshold or (ii) satisfying or not satisfying a threshold.


Features, materials, characteristics, or groups described in conjunction with a particular aspect, embodiment, or example are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith. All of the features disclosed in this specification (including any accompanying claims, abstract, and drawings), or all of the steps of any method or process so disclosed, may be combined in any combination, except combinations where at least some of such features or steps are mutually exclusive. The protection is not restricted to the details of any foregoing embodiments. The protection extends to any novel one, or any novel combination, of the features disclosed in this specification (including any accompanying claims, abstract and drawings), or to any novel one, or any novel combination, of the steps of any method or process so disclosed.


While certain embodiments have been described, these embodiments have been presented by way of example only, and are not intended to limit the scope of protection. Indeed, the novel methods and systems described herein may be embodied in a variety of other forms. Furthermore, various omissions, substitutions and changes in the form of the methods and systems described herein may be made. Those skilled in the art will appreciate that in some embodiments, the actual steps taken in the processes illustrated or disclosed may differ from those shown in the figures. Depending on the embodiment, certain of the steps described above may be removed, others may be added. For example, the actual steps or order of steps taken in the disclosed processes may differ from those shown in the figure. Depending on the embodiment, certain of the steps described above may be removed, others may be added. For instance, the various components illustrated in the figures may be implemented as software or firmware on a processor, controller, ASIC, FPGA, or dedicated hardware. Hardware components, such as processors, ASICs, FPGAs, and the like, can include logic circuitry. Furthermore, the features and attributes of the specific embodiments disclosed above may be combined in different ways to form additional embodiments, all of which fall within the scope of the present disclosure.


User interface screens illustrated and described herein can include additional or alternative components. These components can include menus, lists, buttons, text boxes, labels, radio buttons, scroll bars, sliders, checkboxes, combo boxes, status bars, dialog boxes, windows, and the like. User interface screens can include additional or alternative information. Components can be arranged, grouped, displayed in any suitable order.


Although the present disclosure includes certain embodiments, examples and applications, it will be understood by those skilled in the art that the present disclosure extends beyond the specifically disclosed embodiments to other alternative embodiments or uses and obvious modifications and equivalents thereof, including embodiments which do not provide all of the features and advantages set forth herein. Accordingly, the scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments herein, and may be defined by claims as presented herein or as presented in the future.


Conditional language, such as “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements, or steps. Thus, such conditional language is not generally intended to imply that features, elements, or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements, or steps are included or are to be performed in any particular embodiment. The terms “comprising,” “including,” “having,” and the like are synonymous and are used inclusively, in an open-ended fashion, and do not exclude additional elements, features, acts, operations, and so forth. Also, the term “or” is used in its inclusive sense (and not in its exclusive sense) so that when used, for example, to connect a list of elements, the term “or” means one, some, or all of the elements in the list. Further, the term “each,” as used herein, in addition to having its ordinary meaning, can mean any subset of a set of elements to which the term “each” is applied.


Conjunctive language such as the phrase “at least one of X, Y, and Z,” unless specifically stated otherwise, is otherwise understood with the context as used in general to convey that an item, term, etc. may be either X, Y, or Z. Thus, such conjunctive language is not generally intended to imply that certain embodiments require the presence of at least one of X, at least one of Y, and at least one of Z.


Language of degree used herein, such as the terms “approximately,” “about,” “generally,” and “substantially” as used herein represent a value, amount, or characteristic close to the stated value, amount, or characteristic that still performs a desired function or achieves a desired result. For example, the terms “approximately”, “about”, “generally,” and “substantially” may refer to an amount that is within less than 10% of, within less than 5% of, within less than 1% of, within less than 0.1% of, and within less than 0.01% of the stated amount. As another example, in certain embodiments, the terms “generally parallel” and “substantially parallel” refer to a value, amount, or characteristic that departs from exactly parallel by less than or equal to 15 degrees, 10 degrees, 5 degrees, 3 degrees, 1 degree, or 0.1 degree.


The scope of the present disclosure is not intended to be limited by the specific disclosures of preferred embodiments in this section or elsewhere in this specification, and may be defined by claims as presented in this section or elsewhere in this specification or as presented in the future. The language of the claims is to be interpreted broadly based on the language employed in the claims and not limited to the examples described in the present specification or during the prosecution of the application, which examples are to be construed as non-exclusive.

Claims
  • 1. An apparatus for applying negative pressure to a wound, the apparatus comprising: a source of negative pressure configured to provide negative pressure via a fluid flow path to a wound dressing placed over a wound of a patient, the source of negative pressure comprising an actuator configured to convert an electrical energy to a mechanical energy;a coupling circuit including an inductive reactance;a driving circuit configured to supply a driving signal to the actuator via the coupling circuit to cause the source of negative pressure to provide negative pressure; anda controller configured to control the driving signal supplied by the driving circuit,wherein the coupling circuit comprises an inductor electrically coupled in series between a first output of the driving circuit and a first input of the actuator and an electrical short electrically coupled in series between a second output of the driving circuit and a second input of the actuator.
  • 2. The apparatus of claim 1, wherein the actuator is configured to generate negative pressure by converting the electrical energy to the mechanical energy without converting the electrical energy to a magnetic energy.
  • 3. The apparatus of claim 1, wherein the source of negative pressure comprises a piezoelectric pump, and the actuator comprises a piezoelectric transducer.
  • 4. The apparatus of claim 1, wherein the source of negative pressure comprises a micropump.
  • 5. The apparatus of claim 1, further comprising the wound dressing, the source of negative pressure being disposed on or within the wound dressing.
  • 6. The apparatus of claim 1, wherein the coupling circuit is configured to limit a rate of change over time of the driving signal supplied from the driving circuit to the actuator.
  • 7. The apparatus of claim 1, wherein the inductive reactance is greater than 5 mΩ at an operating frequency of 1 kHz.
  • 8. The apparatus of claim 1, wherein the inductor has an inductance between 1 μH and 100 μH.
  • 9. The apparatus of claim 8, wherein the inductor has a maximum current rating of at least 1 A.
  • 10. The apparatus of claim 1, wherein the driving circuit comprises an H-bridge circuit.
  • 11. The apparatus of claim 1, wherein the controller is further configured to provide a control signal to the driving circuit, and the controller is configured to control the driving signal by adjusting a pulse width modulation of the control signal.
  • 12. The apparatus of claim 1, wherein a magnitude of the driving signal is less than 50 V.
  • 13. The apparatus of claim 1, wherein the driving circuit comprises a boost converter and an H-bridge.
  • 14. A method of treating a wound on a patient, the method comprising: by a negative wound therapy apparatus of claim 1: generating and outputting a control signal;activating a plurality of switches of the driving circuit responsive to the control signal;supplying the driving signal to the actuator of the source of negative pressure via the plurality of switches;limiting a rate of change over time of the driving signal; andsupplying negative pressure with the source of negative pressure to the wound dressing responsive to the driving signal.
  • 15. The method of claim 14, wherein said limiting the rate of change over time comprises limiting the rate of change over time using the coupling circuit.
  • 16. The method of claim 14, wherein said supplying negative pressure is performed by converting the electrical energy to the mechanical energy without converting the electrical energy to a magnetic energy.
  • 17. The method of claim 14, wherein said activating the plurality of switches comprises activating pairs of the plurality of switches responsive to the control signal.
  • 18. The method of claim 14, wherein the control signal comprises a square waveform having a duty cycle of 50%.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. Provisional Application No. 62/331,109, filed May 3, 2016, and U.S. Provisional Application No. 62/479,592, filed Mar. 31, 2017; the disclosures of which are hereby incorporated by reference in their entirety.

PCT Information
Filing Document Filing Date Country Kind
PCT/EP2017/060470 5/3/2017 WO 00
Publishing Document Publishing Date Country Kind
WO2017/191158 11/9/2017 WO A
US Referenced Citations (218)
Number Name Date Kind
3874387 Barbieri Apr 1975 A
4224941 Stivala Sep 1980 A
4398910 Blake et al. Aug 1983 A
4534356 Papadakis Aug 1985 A
4569674 Phillips et al. Feb 1986 A
4624656 Clark et al. Nov 1986 A
4681562 Beck et al. Jul 1987 A
4767943 Adler et al. Aug 1988 A
4979944 Luzsicza Dec 1990 A
5055195 Trasch et al. Oct 1991 A
5055198 Shettigar Oct 1991 A
5056510 Gilman Oct 1991 A
5152757 Eriksson Oct 1992 A
5181905 Flam Jan 1993 A
5266928 Johnson Nov 1993 A
D357743 Bilitz et al. Apr 1995 S
5527293 Zamierowski Jun 1996 A
5549584 Gross Aug 1996 A
5636643 Argenta et al. Jun 1997 A
5643189 Masini Jul 1997 A
5779657 Daneshvar Jul 1998 A
5833646 Masini Nov 1998 A
5902256 Benaron May 1999 A
5964723 Augustine Oct 1999 A
6071267 Zamierowski Jun 2000 A
6142982 Hunt et al. Nov 2000 A
6168800 Dobos et al. Jan 2001 B1
6183438 Berguer Feb 2001 B1
6225523 Masini May 2001 B1
6261276 Reitsma Jul 2001 B1
6261283 Morgan et al. Jul 2001 B1
6398767 Fleischmann Jun 2002 B1
6458109 Henley et al. Oct 2002 B1
6471982 Lydon et al. Oct 2002 B1
6599262 Masini Jul 2003 B1
6607495 Skalak et al. Aug 2003 B1
6685681 Lockwood et al. Feb 2004 B2
6787682 Gilman Sep 2004 B2
6794554 Sessions et al. Sep 2004 B2
6800074 Henley et al. Oct 2004 B2
6855135 Lockwood et al. Feb 2005 B2
6942633 Odland Sep 2005 B2
6951553 Bubb et al. Oct 2005 B2
6979324 Bybordi et al. Dec 2005 B2
7004915 Boynton et al. Feb 2006 B2
7022113 Lockwood et al. Apr 2006 B2
7067709 Murata et al. Jun 2006 B2
7070584 Johnson et al. Jul 2006 B2
7087806 Scheinberg et al. Aug 2006 B2
7108683 Zamierowski Sep 2006 B2
7338482 Lockwood et al. Mar 2008 B2
7361184 Joshi Apr 2008 B2
7524315 Blott et al. Apr 2009 B2
7553306 Hunt et al. Jun 2009 B1
7569742 Haggstrom et al. Aug 2009 B2
7611500 Lina et al. Nov 2009 B1
7615036 Joshi et al. Nov 2009 B2
D605775 Koch et al. Dec 2009 S
D608007 Arbesman et al. Jan 2010 S
7645253 Gura et al. Jan 2010 B2
7687678 Jacobs Mar 2010 B2
7699823 Haggstrom et al. Apr 2010 B2
7776028 Miller et al. Aug 2010 B2
D625422 Arbesman et al. Oct 2010 S
7815616 Boehringer et al. Oct 2010 B2
7837673 Vogel Nov 2010 B2
7846141 Weston Dec 2010 B2
7896864 Lockwood et al. Mar 2011 B2
7922676 Daskal et al. Apr 2011 B2
7922703 Riesinger Apr 2011 B2
7942866 Radl et al. May 2011 B2
7959624 Riesinger Jun 2011 B2
7976519 Bubb et al. Jul 2011 B2
8007257 Heaton et al. Aug 2011 B2
8007481 Schuessler et al. Aug 2011 B2
8062272 Weston Nov 2011 B2
8080702 Blott et al. Dec 2011 B2
8092441 Sugito Jan 2012 B2
8158844 Mcneil Apr 2012 B2
8167869 Wudyka May 2012 B2
8212100 Moore Jul 2012 B2
8215929 Shen et al. Jul 2012 B2
8323264 Weston et al. Dec 2012 B2
8371829 Jaeb et al. Feb 2013 B2
8372049 Jaeb et al. Feb 2013 B2
8372050 Jaeb et al. Feb 2013 B2
8404921 Lee et al. Mar 2013 B2
8409160 Locke et al. Apr 2013 B2
8414519 Hudspeth et al. Apr 2013 B2
8419696 Wilkes Apr 2013 B2
8425478 Olson Apr 2013 B2
8439894 Miller May 2013 B1
8449508 Coulthard et al. May 2013 B2
8500776 Ebner Aug 2013 B2
8529548 Blott et al. Sep 2013 B2
8545466 Andresen et al. Oct 2013 B2
8579872 Coulthard et al. Nov 2013 B2
8603074 Kagan Dec 2013 B2
8604265 Locke et al. Dec 2013 B2
8641691 Fink et al. Feb 2014 B2
8641693 Locke et al. Feb 2014 B2
8702665 Locke et al. Apr 2014 B2
8764732 Hartwell Jul 2014 B2
8795257 Coulthard et al. Aug 2014 B2
8808274 Hartwell Aug 2014 B2
8814842 Coulthard et al. Aug 2014 B2
8821458 Locke et al. Sep 2014 B2
8870837 Locke et al. Oct 2014 B2
8905985 Allen et al. Dec 2014 B2
8915895 Jaeb et al. Dec 2014 B2
8961496 Locke et al. Feb 2015 B2
8974429 Gordon et al. Mar 2015 B2
9050209 Coulthard et al. Jun 2015 B2
9061095 Adie et al. Jun 2015 B2
9084845 Adie et al. Jul 2015 B2
9089630 Perkins et al. Jul 2015 B2
9198802 Robinson et al. Dec 2015 B2
9259558 Tsai Feb 2016 B2
9265665 Robinson et al. Feb 2016 B2
9283118 Locke et al. Mar 2016 B2
9393354 Freedman et al. Jul 2016 B2
9414968 Heagle Aug 2016 B2
9421133 Hu et al. Aug 2016 B2
9427505 Askem et al. Aug 2016 B2
9452088 Shulman et al. Sep 2016 B2
9560975 Mei et al. Feb 2017 B2
D787690 Mackay et al. May 2017 S
9737649 Begin et al. Aug 2017 B2
9770368 Robinson et al. Sep 2017 B2
9814811 Aalders et al. Nov 2017 B2
9907703 Allen et al. Mar 2018 B2
9925092 Luckemeyer et al. Mar 2018 B2
RE46778 Peron Apr 2018 E
9956120 Locke May 2018 B2
10004914 Nettesheim et al. Jun 2018 B2
10010656 Jaeb et al. Jul 2018 B2
10016544 Coulthard et al. Jul 2018 B2
10046095 Middaugh et al. Aug 2018 B1
10046096 Askem et al. Aug 2018 B2
10086117 Locke et al. Oct 2018 B2
20030014022 Lockwood Jan 2003 A1
20030212357 Pace Nov 2003 A1
20040076662 Riesinger Apr 2004 A1
20040087884 Haddock et al. May 2004 A1
20040167482 Watson Aug 2004 A1
20050012616 Forster et al. Jan 2005 A1
20050045461 Sweetland et al. Mar 2005 A1
20050065471 Kuntz Mar 2005 A1
20050119737 Bene et al. Jun 2005 A1
20050137539 Biggie et al. Jun 2005 A1
20060029650 Coffey Feb 2006 A1
20060086598 Sneek et al. Apr 2006 A1
20060107642 Smith et al. May 2006 A1
20060259102 Slatkine Nov 2006 A1
20070055209 Patel et al. Mar 2007 A1
20070128055 Lee Jun 2007 A1
20070179460 Adahan Aug 2007 A1
20070225663 Watt et al. Sep 2007 A1
20070255187 Branch Nov 2007 A1
20070265586 Joshi et al. Nov 2007 A1
20080021356 Castello Escude Jan 2008 A1
20080051716 Stutz Feb 2008 A1
20090012484 Nielsen et al. Jan 2009 A1
20090048556 Durand Feb 2009 A1
20100022990 Karpowicz et al. Jan 2010 A1
20100100160 Edman et al. Apr 2010 A1
20100137775 Hu et al. Jun 2010 A1
20100160881 Lin et al. Jun 2010 A1
20100280469 Hall et al. Nov 2010 A1
20100292632 Mulvihill et al. Nov 2010 A1
20110092927 Wilkes et al. Apr 2011 A1
20110112492 Bharti et al. May 2011 A1
20110190670 Jaeb Aug 2011 A1
20110224631 Simmons et al. Sep 2011 A1
20110288510 Locke Nov 2011 A1
20110292623 Stanley Dec 2011 A1
20110305736 Wieland et al. Dec 2011 A1
20120059294 Schubert et al. Mar 2012 A1
20120109034 Locke et al. May 2012 A1
20120109083 Coulthard May 2012 A1
20130215638 Dabov et al. Aug 2013 A1
20140100536 Angel Apr 2014 A1
20140343518 Riesinger Nov 2014 A1
20150057625 Coulthard Feb 2015 A1
20150100045 Allen Apr 2015 A1
20150202354 Wall Jul 2015 A1
20160015873 Robinson et al. Jan 2016 A1
20160166438 Rovaniemi Jun 2016 A1
20160199546 Chao Jul 2016 A1
20160242964 Rapp et al. Aug 2016 A1
20160271305 Kurihara et al. Sep 2016 A1
20160361473 Robinson et al. Dec 2016 A1
20170112974 Fujisaki Apr 2017 A1
20170112975 Fujisaki Apr 2017 A1
20170127525 Schonholz May 2017 A1
20170232189 Qin et al. Aug 2017 A1
20170296714 Locke et al. Oct 2017 A1
20170319761 Locke et al. Nov 2017 A1
20170326277 Huang Nov 2017 A1
20170368239 Askem et al. Dec 2017 A1
20180008760 Zilbershlag et al. Jan 2018 A1
20180021178 Locke et al. Jan 2018 A1
20180028728 Aarestad et al. Feb 2018 A1
20180055977 Pratt et al. Mar 2018 A1
20180104393 Wu et al. Apr 2018 A1
20180200414 Askem et al. Jul 2018 A1
20180272052 Locke et al. Sep 2018 A1
20180296397 Askem et al. Oct 2018 A1
20180318137 Donda et al. Nov 2018 A1
20180318165 Donda et al. Nov 2018 A1
20180353771 Kim et al. Dec 2018 A1
20190021911 Askem et al. Jan 2019 A1
20190142644 Askem et al. May 2019 A1
20190143007 Askem et al. May 2019 A1
20190159938 Askem et al. May 2019 A1
20190192350 Gowans et al. Jun 2019 A1
20190282737 Beadle et al. Sep 2019 A1
20200022846 Beadle et al. Jan 2020 A1
Foreign Referenced Citations (165)
Number Date Country
201664463 Dec 2010 CN
19844355 Apr 2000 DE
0512543 Nov 1992 EP
1411874 Apr 2004 EP
1455701 Mar 2006 EP
1448261 Feb 2007 EP
1807032 Jul 2007 EP
1476217 Mar 2008 EP
1976477 Oct 2008 EP
1507498 Jul 2009 EP
1791579 Jul 2009 EP
2109472 Oct 2009 EP
1947987 May 2010 EP
1358456 Jul 2010 EP
2214728 Aug 2010 EP
2279016 Feb 2011 EP
2326295 Jun 2011 EP
2340064 Jul 2011 EP
2346468 Jul 2011 EP
2349155 Aug 2011 EP
2205190 Sep 2011 EP
2370116 Oct 2011 EP
2531761 Dec 2012 EP
2231088 Jan 2013 EP
2015655 Mar 2013 EP
2285323 Mar 2013 EP
2563421 Mar 2013 EP
2049055 Apr 2013 EP
2340066 Apr 2013 EP
2440260 May 2013 EP
2340062 Jun 2013 EP
2603699 Jun 2013 EP
1893145 Jul 2013 EP
2370142 Jul 2013 EP
2279017 Aug 2013 EP
2370117 Aug 2013 EP
2258443 Sep 2013 EP
2263742 Sep 2013 EP
1848390 Dec 2013 EP
1875081 Dec 2013 EP
2271381 Dec 2013 EP
2160166 Jan 2014 EP
1565219 Feb 2014 EP
2305325 Apr 2014 EP
2323712 Apr 2014 EP
2451498 Apr 2014 EP
2051675 Jun 2014 EP
1485613 Jul 2014 EP
1545644 Aug 2014 EP
2349154 Aug 2014 EP
2146759 Sep 2014 EP
2416816 Oct 2014 EP
2468323 Oct 2014 EP
2658493 Oct 2014 EP
1850818 Dec 2014 EP
2268348 Dec 2014 EP
2561128 Jan 2015 EP
2829287 Jan 2015 EP
2683285 Feb 2015 EP
2470136 Mar 2015 EP
2503974 May 2015 EP
2249894 Aug 2015 EP
2802366 Aug 2015 EP
2438302 Sep 2015 EP
2346545 Oct 2015 EP
2438301 Oct 2015 EP
2802304 Dec 2015 EP
2852421 Jan 2016 EP
2410962 Mar 2016 EP
2640436 Mar 2016 EP
2855937 May 2016 EP
2433594 Jun 2016 EP
2919730 Jun 2016 EP
2861869 Jul 2016 EP
2945584 Jul 2016 EP
2293749 Aug 2016 EP
2305327 Oct 2016 EP
2467086 Oct 2016 EP
2470135 Oct 2016 EP
2767305 Oct 2016 EP
2282788 Dec 2016 EP
2462956 Mar 2017 EP
3139878 Mar 2017 EP
2249761 Apr 2017 EP
1587502 May 2017 EP
1587554 May 2017 EP
2731563 May 2017 EP
2968871 Jul 2017 EP
2632613 Aug 2017 EP
2781208 Aug 2017 EP
2888478 Aug 2017 EP
2937107 Aug 2017 EP
2967627 Aug 2017 EP
3062751 Aug 2017 EP
3139879 Aug 2017 EP
2359784 Sep 2017 EP
3151795 Sep 2017 EP
2367518 Oct 2017 EP
2675493 Oct 2017 EP
3068455 Oct 2017 EP
2558046 Nov 2017 EP
2736548 Nov 2017 EP
3052158 Nov 2017 EP
2593058 Mar 2018 EP
3139880 Mar 2018 EP
1496822 Aug 2018 EP
2879633 Aug 2018 EP
2227203 Sep 2018 EP
2696826 Sep 2018 EP
3106186 Sep 2018 EP
3162330 Sep 2018 EP
3169382 Sep 2018 EP
3203953 Sep 2018 EP
2941280 Oct 2018 EP
3244852 Oct 2018 EP
2687241 Nov 2018 EP
2687243 Nov 2018 EP
3062753 Nov 2018 EP
3120879 Dec 2018 EP
3191149 Jan 2019 EP
2370130 Mar 2019 EP
3053609 Mar 2019 EP
3180048 Mar 2019 EP
3452131 Mar 2019 EP
3143974 Apr 2019 EP
2285432 Jun 2019 EP
3050545 Jul 2019 EP
3319656 Aug 2019 EP
2355762 Sep 2019 EP
2822613 Sep 2019 EP
2863855 Sep 2019 EP
2482912 Oct 2019 EP
3038667 Oct 2019 EP
3129095 Oct 2019 EP
3191150 Oct 2019 EP
3280466 Oct 2019 EP
2244756 Dec 2019 EP
2968702 Dec 2019 EP
2939320 Jun 2010 FR
2511523 Sep 2014 GB
H04354722 Dec 1992 JP
H0870590 Mar 1996 JP
131622 Aug 2013 RU
WO-2009098696 Aug 2009 WO
WO 2009124100 Oct 2009 WO
WO-2009120951 Oct 2009 WO
WO-2011130570 Oct 2011 WO
WO 2011146535 Nov 2011 WO
WO-2011135285 Nov 2011 WO
WO-2011144888 Nov 2011 WO
WO-2012078723 Jun 2012 WO
WO-2014099709 Jun 2014 WO
WO 2015115516 Aug 2015 WO
WO 2016006458 Jan 2016 WO
WO-2016126560 Aug 2016 WO
WO-2017079174 May 2017 WO
WO-2017196888 Nov 2017 WO
WO-2018056060 Mar 2018 WO
WO-2018115461 Jun 2018 WO
WO-2018156730 Aug 2018 WO
WO-2018158250 Sep 2018 WO
WO-2018162613 Sep 2018 WO
WO-2018164803 Sep 2018 WO
WO-2018185138 Oct 2018 WO
WO-2018192978 Oct 2018 WO
Non-Patent Literature Citations (2)
Entry
International Search Report and Written Opinion, re PCT Application No. PCT/EP2017/060470, dated Aug. 4, 2017.
International Preliminary Report on Patentability for Application No. PCT/EP2017/060470, dated Nov. 15, 2018, 8 pages.
Related Publications (1)
Number Date Country
20190125943 A1 May 2019 US
Provisional Applications (2)
Number Date Country
62479592 Mar 2017 US
62331109 May 2016 US